Evaluation of the Prevalence of anomalIes of Glucose Metabolism in Patients Undergoing a Coronary Artery Bypass Graft (CABG)

Evaluation of the Prevalence of anomalIes of Glucose Metabolism in Patients Undergoing a Coronary Artery Bypass Graft, Consequences for Morbi/Mortality in the Short and Medium Term

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02855879

Acronym

IMPACT

Enrollment

286

Registered

2016-08-04

Start date

2015-04-08

Completion date

2019-06-05

Last updated

2019-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anomalies in Glucose Metabolism, Coronary Artery Bypass Graft

Brief summary

The aim of this study is to determine the prevalence of diabetes and non-diabetic glucose metabolism anomalies (glucose intolerance, non-diabetic fasting hyperglycaemia in patients about to undergo coronary artery bypass grafting (CABG). In addition, the effect of these anomalies on post CABG morbi/mortality in the short term will be evaluated.

Interventions

OTHERCollection of biological data

OTHERCollection of clinical data

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* persons who have provided oral consent * patients about to undergo coronary artery bypass grafting * age \>18 years

Exclusion criteria

* persons without national health insurance cover * Adults under guardianship * Pregnant or breast-feeding women

Design outcomes

Primary

Measure	Time frame
Percentage of glucose anomalies (non-diabetic fasting hyperglycaemia, glucose intolerance, diabetes) in CAD patients about to undergo coronary artery bypass grafting.	Change from inclusion to week 2 and up to month 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026